Investor.News is pleased to announce an upcoming InvestorTalk scheduled for tomorrow, Thursday, February 6th, at 9 AM EST, featuring Brent Willis, President, CEO, and Director of Voyageur Pharmaceuticals Ltd. (TSXV: VM). To participate in this engaging discussion, please click here
Voyageur Pharmaceuticals develops barium and iodine APIs and high-performance imaging contrast agents. It aims to vertically integrate the contrast market by producing its own APIs and endohedral fullerene drugs (C60), with five licensed barium products from Health Canada. Voyageur partners with GMP-certified manufacturers in Canada to validate its products globally and plans to become a domestic manufacturer of radiology drugs, enhancing profitability. Owning a 100% interest in the Frances Creek barium sulphate project, Voyageur sources high-grade minerals that surpass the quality of synthetic alternatives, aiming to lower costs and improve product quality. Embracing a “From the Earth to the Bottle” philosophy, Voyageur seeks to be the first vertically integrated firm in the radiology contrast media market, controlling costs from raw material to production to ensure quality and efficiency.
In preparation for tomorrow’s InvestorTalk, here are the three most recent news releases from Voyageur Pharmaceuticals for your review, which are listed below:
- January 23, 2025 – Voyageur Secures $687k of Additional Capital from Warrant Exercises — click here
- January 15, 2025 – Voyageur Recaps Significant 2024 Achievements and Unveils Plans for Transformational 2025, Including Market Launch for Barium Suite of Products and Advancement of Iodine Suite — click here
- January 13, 2025 – Voyageur Commences Testing of Innovative Barium Contrast Product Line in Human Radiology Scans, Paving the Way for Near-Term Market Launch — click here
We found the January 15th news release titled, “Voyageur Recaps Significant 2024 Achievements and Unveils Plans for Transformational 2025, Including Market Launch for Barium Suite of Products and Advancement of Iodine Suite” particularly noteworthy and here are 5 key data points from it:
- Introduction of New Products: In September 2024, Voyageur introduced five new Health Canada licensed barium contrast products. These products aim to set new standards within the medical imaging industry by enhancing diagnostic capabilities. They are currently undergoing clinical evaluations.
- Strategic Alliances and Partnerships: Voyageur entered into a Letter of Intent (LOI) with a large multinational pharmaceutical company on December 20, 2024, to collaborate on the production of contrast media products. This partnership is expected to help Voyageur expand into other contrast media markets and is working towards a definitive agreement in early 2025.
- Technological Innovations: In collaboration with Rain Cage Carbon Inc., Voyageur achieved a technological breakthrough by successfully producing the first of multiple anticipated endohedral fullerenes using the RC Carbon Capture Eden™ System. This innovation will allow the development of new diagnostic imaging drugs.
- Market Expansion and Sales Contracts: Voyageur secured its first significant sales contract on May 28, 2024, for CAD $2.7 million with the SmoothX 2% Barium Contrast for the Latin American market. They are also in discussions with multiple global distributors to expand their market presence.
- Future Objectives and Projects: For 2025, Voyageur is focused on several strategic initiatives including patient testing of barium contrasts, expanding Canadian sales, pursuing FDA licensing, advancing the Frances Creek barium contrast project, and developing the iodine contrast project in the USA to create cost-effective drugs. These efforts are part of their broader strategy to establish a secure, vertically integrated supply chain for the North American radiology drug industry.
(02.05.2025 at 6:00 AM EST, Source)
For more information on Voyageur Pharmaceuticals Ltd., click here
For more information on the InvestorTalk pre-market series, go to InvestorTalk.com.
Leave a Reply